Vedolizumab

ATC Code L04AG05

Vedolizumab

Definition

A recombinant humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the human lymphocyte Peyer's patch adhesion molecule 1 (LPAM-1; alpha4beta7; a4b7), with immunomodulating, anti-inflammatory, and potential antineoplastic activities. Upon administration, vedolizumab selectively binds to integrin a4b7 and prevents the binding of a4b7, expressed on the surface of a subset of T-lymphocytes, to its natural ligand, mucosal addressin cell adhesion molecule-1 (MAdCAM-1), which is mainly expressed on the surface of gut endothelial cells. This prevents a4b7-mediated signaling, adhesion of lymphocytes to the endothelium and the migration of T-lymphocytes across the endothelium into inflamed gastrointestinal (GI) tissue. By preventing this infiltration to the affected area, inflammation is reduced. The human lymphocyte a4b7 integrin, plays a key role in gastrointestinal (GI) inflammation; it is overexpressed in certain types of cancer cells. The alpha4beta7/MAdCAM-1 signaling pathway plays a critical role in the homing of T-lymphocytes to intestinal tissue.

Also known as Entyvio, Immunoglobulin G1, Anti-(Human Integrin LPAM-1 (Lymphocyte Peyer's Patch Adhesion Molecule 1)) (Human-Mus musculus Heavy Chain), Disulfide with Human-Mus musculus kappa-chain, Dimer, LDP 02, LDP-02, LDP02, MLN0002, MLN02, VEDOLIZUMAB — per NCIT

Also identified as

Indications

Disease Relation Source
Crohn's disease may treat MEDRT · Public domain (U.S. Government work)
Enteritis may treat MEDRT · Public domain (U.S. Government work)
Ulcerative colitis may treat MEDRT · Public domain (U.S. Government work)

Organ Effects

Organ Side effect / interaction Source
Alimentary part of gastrointestinal system may treat a disease of this organ DERIVED · CC BY 4.0
Intestine may treat a disease of this organ DERIVED · CC BY 4.0
Small intestine may treat a disease of this organ DERIVED · CC BY 4.0

3 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.